Press Releases

Subscribe to our mailing list to receive the latest news.
To browse our press releases, simply click on the year that interests you to view the documents.

Validity of Neptune’s Patent Upheld by Australian Patent Office / Third Challenge by Enzymotec Fails
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX
Neptune Announces Q2 FY 2017 Results
Neptune to Hold Conference Call to Discuss Second Quarter Results FY2017
Neptune signs an exclusive worldwide agreement for MaxSimil
Neptune and Aker BioMarine reach important patent agreement
Neptune Introduces NKO Omega Plus
Acasti, a Neptune Subsidiary, Announces CaPre Bridging Results
Neptune Announces the Election of its Directors and Change of Fiscal Year End
Neptune Announces First Quarter Results 2017
Neptune Announces Fourth Quarter and Fiscal Year Results
Neptune Announces Preliminary Q4 Results Record Revenue and Positive Adjusted EBITDA
Neptune Announces Third Quarter Results
Neptune to Hold Conference Call to Discuss Third Quarter Results
Neptune Announces Term Loan Financing
Neptune Acquires Biodroga, Creating New Growth Platform

Financial results

To browse our annual reports, simply click on the year that interests you to view the documents.

Annual and Quarterly Reports

A. Management Discussion & Analysis (MD&A)
B. Neptune Audited Financial Statements 2015-2016
C. Annual Information Form 2016 - Anglais seulement
D. Notice of Meeting 2016
E. Proxy Circular 2016
F. Proxy Form 2016
Neptune Financial Statements Q3 2015-2016
Neptune Quarterly Report Q3 2015-2016
Neptune Financial Statements Q2 2015-2016
Neptune Quarterly Report Q2 2015-2016
Neptune Financial Statements Q1 2015-2016
Neptune Quarterly Report Q1 2015-2016
Neptune is driven by a passionate leadership team backed by years of industry experience and in-depth knowledge of pharmaceutical, biotech and nutritional supplements.
Board of Directors Management Team
Discover Neptune’s holistic approach to creating stakeholder value.
John Chu
Desjardins Securities

Gerald Pascarelli
Cowen & Company

Douglas W. Loe
Echelon Wealth Partners

Douglas Miehm